35 results about "Ursodesoxycholic acid" patented technology

The invention discloses a biochemical immunodetection device and a biochemical immunodetection method for ursodesoxycholic acid reduzate, and belongs to the technical field of ursodesoxycholic acid reduzate detection. The ursodesoxycholic acid reduzate detection device comprises a detection box and a lifter at the bottom of the detection box, a dissolution preparation part and a centrifugal part are arranged in the detection box, and the dissolution preparation part can fully dissolve an ursodesoxycholic acid reduzate-containing medicament; the centrifugal part is used for carrying out precipitation separation on the dissolved medicament; the detector can accurately collect fluorescence signals of the immune complex; according to the ursodesoxycholic acid reduzate detection device, the integrated operation of detection test tube fixing, cover opening and transferring, medicament adding, cover closing and plug sealing and dissolving is achieved, the steps of automatic medicament filling, sealing and the like are achieved, the medicament preparation efficiency is greatly improved, efficient and accurate detection of ursodesoxycholic acid reduzate is further achieved, and the detection efficiency is improved. And complex and tedious manual operation is avoided, and the situation that the sample is easily polluted by manual operation is avoided.

The invention relates to the technical field of health wine preparation, and discloses a multi-effect synergistic enhanced bear gall body-building wine compound preparation process which comprises the following steps: taking sorghum, corn and fructus lycii as fermentation base materials, and carrying out double-strain synergistic fermentation by adopting saccharomyces cerevisiae and lactobacillus plantarum; adding fresh ursodesoxycholic acid during fermentation, carrying out in-situ enzymatic debinding conversion by using a compound enzyme system generated by a fermentation system, and converting the bound bile acid into free ursodesoxycholic acid; after fermentation, distilling to obtain raw wine; a molecularly imprinted polymer prepared by taking a wolfberry polyphenol key monomer as a template molecule is adopted to carry out targeted anchoring refining on raw wine, selective capture and enrichment of wolfberry polyphenol are carried out, and finally aging is carried out to obtain a finished product. According to the method disclosed by the invention, upstream double-strain fermentation in-situ enzymatic conversion and downstream molecular imprinting targeted refining are systematically integrated, so that the technical contradictions that the conversion rate of combined bile acid is low and a large amount of polyphenol functional components are synchronously lost during purification and impurity removal in a traditional process are solved.

The invention relates to the field of biological catalysis, and discloses a method and a device for generating ursodesoxycholic acid through continuous flow catalysis of chenodeoxycholic acid. Comprising the following steps: (1) in the presence of first immobilized cells, carrying out a first catalytic reaction on a reaction system containing chenodeoxycholic acid to obtain a first product, the first immobilized cells expressing 7 alpha-hydroxysteroid dehydrogenase and lactic dehydrogenase; the concentration of the chenodeoxycholic acid in the reaction system is 40 to 70 mM; (2) adjusting the pH value of the first product to 8-9, and then in the presence of a second immobilized cell, carrying out a second catalytic reaction on the first product after the pH value is adjusted to obtain ursodesoxycholic acid, and the second immobilized cell expresses 7 beta-hydroxysteroid dehydrogenase and glucose dehydrogenase. According to the method, the stable activity of a catalytic system is kept, efficient conversion of high-concentration CDCA is achieved, meanwhile, precipitation of 7-KLCA is thoroughly avoided, and the synthesis efficiency, the product purity and the process continuity of UDCA are remarkably improved.

The invention discloses an ursodesoxycholic acid-pterostilbene conjugate, a preparation method thereof and application of the ursodesoxycholic acid-pterostilbene conjugate in preparation of drugs for treating non-alcoholic fatty liver diseases, and belongs to the technical field of biological medicines. According to the conjugate, ursodesoxycholic acid and pterostilbene are covalently connected through specific chemical bridging, and the structural general formula is shown in the specification. The preparation method comprises the following steps: respectively preparing the alkynyl-containing pterostilbene derivative and the azido-containing ursodesoxycholic acid derivative through esterification and amidation reactions, and then realizing efficient coupling through a click chemical reaction. The conjugate provided by the invention can realize hepatic targeting delivery by virtue of a bile acid transporter, synchronously releases two active components in hepatic cells, plays a therapeutic role through multiple mechanisms such as synergistic regulation of lipid metabolism, inhibition of oxidative stress and inflammation, anti-fibrosis and the like, and is obviously superior to a single component or a physical mixture; and a new strategy is provided for treatment of the non-alcoholic fatty liver disease.

Improved enantioselective enzymatic processes for preparing ursodeoxycholic acid with high pharmaceutical purity are provided. Also provided are improved enantioselective enzymatic processes for preparing ursodeoxycholic acid with high yield and high pharmaceutical and enantiomeric purity.

The invention belongs to the technical field of medicines and the field of acne treatment, and particularly relates to application of amorphous salt in preparation of a medicine for treating acne and the medicine. The amorphous salt is prepared by reacting ursodesoxycholic acid and matrine, preferably, the ursodesoxycholic acid and the matrine are dissolved in a proper solvent according to the molar ratio of 1: (0.5-2), then the solvent is rapidly removed, and remaining solids are further dried and crushed to obtain the ursodesoxycholic acid / matrine amorphous salt. The solubility and the percutaneous penetration rate of the propionibacterium acnes are remarkably improved, the propionibacterium acnes can be inhibited, the expression of IL-1beta, IL-6, IL-8 and TNF-alpha can be reduced, P65 protein nucleus translocation can be inhibited, and an efficient and safe new scheme is provided for acne treatment.

The application discloses an intelligent response type bear gall powder-based bioactive ceramic hydrogel wound repair system and belongs to the technical field of biomedical materials, and solves the problems of split functions, uncontrollable release and unreasonable interface combination of existing wound dressings. The system innovatively combines intelligent response type hydrogel, bioactive ceramic and active components of bear gall powder through dynamic coordination bonds. The coordination bond formed by the active groups of bear gall powder and metal ions released by the ceramic serves as an intelligent switch, can respond to changes in wound pH / ROS, and accurately controls the release of antibacterial ions and anti-inflammatory components. Meanwhile, the bond realizes the stable and dynamic combination of the ceramic and the gel. The application realizes the organic unity of intelligent response, multiple bioactivity and stable structure, can synergistically resist bacteria, inflammation and promote repair, and improves the quality of wound healing.

The invention relates to the technical field of food processing and biology, discloses a genetic analysis bear gall body-building wine liver and stomach maintenance and immunity enhancement process, and solves the problems of unstable quality, low component dissolution rate and fuzzy efficacy orientation caused by fluctuation of raw material components and single soaking process in the prior art. Comprising the following steps: carrying out biochemical fingerprint analysis on fresh ursodesoxycholic acid and fructus lycii, and carrying out efficacy typing according to the contents of ursodesoxycholic acid, lycium barbarum polysaccharide, betaine and the like; carrying out targeted bio-enzyme pretreatment on the specific Chinese wolfberry fruits according to the typing result; raw materials of specific types are subjected to efficacy coupling combination, stepped dynamic alcoholysis soaking is adopted, and components with different dissolution characteristics are fully extracted through low-alcohol pre-dissolution and gradient alcohol rising steps; and finally, filtering, harmonizing and alcoholizing. According to the scheme, raw material standardization and process precision are combined, so that the stability of product quality is ensured, the transfer rate of functional components is increased, and liver and stomach nourishing or immunity enhancing products with definite efficacy can be directionally prepared.

The invention discloses a silanization purification method for ursodesoxycholic acid prepared by a biological enzyme method, and belongs to the field of biological pharmacy. According to the method, the whole-cell reaction liquid is used as a purification object, insoluble macromolecular impurities are removed through preliminary impurity removal and high-concentration acetone-water dissolution, the target content of UDCA is 80% or above successfully, and the product is pure white; the method comprises the following steps: carrying out a reaction on a UDCA silanization derivative and-OH by using a silanization reagent, separating the UDCA silanization derivative from other silanization derivatives, and hydrolyzing the UDCA silanization derivative to realize purification of UDCA. The content of CDCA in the final product is effectively controlled to be 0.5% or below, the purity of the UDCA crude product is improved from 53% to 98.5% or above, and the requirements of UDCA bulk drugs are met. The method is simple in process and low in cost, the obtained product is high in purity, the chenodeoxycholic acid impurity content is low, and the chenodeoxycholic acid can be used as a raw material of a pharmaceutical preparation.

The present invention relates to compounds that derive from bile acids, such as ursodeoxycholic acid and to their use in the prevention and / or treatment of cancer, in particular of cholangiocarcinoma.

The invention relates to the technical field of biomedicine, and particularly discloses an in-vitro diagnosis marker for gall-stone and application thereof.The in-vitro diagnosis marker is jointly composed of a metabolism marker and an inflammation marker, the metabolism marker is the concentration ratio of lithocholic acid to ursodesoxycholic acid (LCA / UDCA), and the inflammation marker is the concentration ratio of CD133 to lipopolysaccharide (CD133 / LPS); the invention further provides a kit containing the marker and a detection method of the kit. The kit integrates specific detection reagents for LCA, UDCA, CD133 and LPS, two specific value markers can be rapidly, sensitively and simultaneously detected through an optimized sample treatment and detection process, and result judgment is carried out based on a preset reference interval upper limit and a composite judgment rule.

The invention relates to the field of biology, in particular to application of tauroursodeoxycholic acid in preparation of a medicine for promoting function maturation of islet organs. The specific effect of tauroursodeoxycholic acid in promoting functional maturation of iPSC-derived islet-like organs is found and verified for the first time, and a brand new treatment thought is represented. The beta cell functional gene expression and glucose stimulation response capability of the sc-islet can be remarkably improved only by performing TUDCA treatment for 96 hours, and the function maturation period is greatly shortened. The obvious effect can be achieved by adopting the low-dose TUDCA with the concentration of 25-100 ng / mL, the cost is reduced, and the potential toxicity risk is reduced. Key indexes (functional gene expression and glucose response) of beta cell maturation are directly targeted, and a high-quality cell model is provided for research and treatment of diabetes mellitus.

The invention relates to the technical field of biological medicine chemical separation, and discloses a separation and purification process of high-purity ursodesoxycholic acid mother liquor, which comprises the following steps: adding alkaline amino acid into the mother liquor containing ursodesoxycholic acid, stirring and dissolving to obtain a water phase system; adding a neutral chiral hydrophobic deep-eutectic solvent formed by complexing L-menthol and long-chain fatty alcohol into the water-phase system, and carrying out mixed extraction; standing for layering, separating to remove an upper-layer oil phase, and collecting a lower-layer water phase; finally, acid is added into the water phase to adjust the pH value, and an ursodesoxycholic acid product is obtained through ultrasonic-assisted crystallization, cleaning and drying. According to the method disclosed by the invention, efficient separation of a target product from chenodeoxycholic acid and lithocholic acid is realized by utilizing the specific hydrophilic anchoring effect of the basic amino acid on ursodeoxycholic acid and cooperating with the chiral hydrophobic recognition effect of the eutectic solvent on impurities. The process is green and environment-friendly, the solvent can be recycled, and the obtained product is high in purity and suitable for industrial application.

The utility model relates to the technical field of chemical separation, and discloses a modularized low-pressure ursodesoxycholic acid separation assembly which comprises a material disc, a partition plate is fixedly connected to the inner wall of the material disc, a connecting disc is rotatably connected to the lower surface of the material disc, and a stirring cabin is fixedly connected to the lower surface of the connecting disc. A second discharging pipe is fixedly connected to the interior of the stirring bin, a first valve is rotationally connected to one side of the outer wall of the second discharging pipe, a filtering bin is fixedly connected to the outer wall of the second discharging pipe, and a filtering assembly is arranged on one side of the inner wall of the filtering bin and comprises a sliding rail. According to the utility model, the effect of enabling materials to enter the filtering cabin is achieved by opening the valve I, the effect of carrying out multi-stage filtering on the materials is achieved by installing the coarse filtering net and the fine filtering net in the filtering cabin, and the effect of effectively improving the purity and the quality of products is achieved by carrying out finer and more thorough separation on the materials.

The invention relates to the field of medicine, in particular to solid dosage forms for the treatment of primary biliary cholangitis (PBC). The invention provides a modified release solid dosage form comprising two active pharmaceutical ingredients, obeticholic acid and ursodeoxycholic acid, arranged to release sequentially over time. The solid dosage form is designed to achieve a controlled, separate release of each API to provide a desired therapeutic profile.

This invention relates to a capsule wall material for improving the stability of ursodeoxycholic acid and its preparation method, belonging to the field of capsule wall material preparation technology. Specifically, it includes the following steps: acylation modification of soybean protein followed by preparation of a moisture-proof layer material with an enteric coating material; mixing gelatin, carboxymethyl cellulose, glycerin, polyvinylpyrrolidone, sugars, and metal salts, adding water, and stirring to form a capsule base; molding hollow capsule shells using a mold; uniformly spraying the moisture-proof layer material onto the capsule shell surface, followed by low-temperature drying and curing to form a composite wall material with both light-shielding properties and high mechanical strength. By introducing a moisture-proof layer material prepared from modified soybean protein and an enteric coating material, moisture can be prevented from eroding the drug inside the capsule, further ensuring the stability and shelf life of the drug. The resulting capsule wall material effectively protects ursodeoxycholic acid, preventing its degradation or inactivation during storage and use, thereby improving the stability and efficacy of the drug.

The invention discloses application of ursodesoxycholic acid as a natural EGFR (epidermal growth factor receptor) inhibitor in preparation of a medicine for preventing and treating colitis-associated colorectal cancer, and belongs to the technical field of biological medicines. According to the application, a new application of ursodesoxycholic acid serving as a natural EGFR inhibitor which has high safety and a multi-target synergistic effect and is used for preventing and treating colitis-related colorectal cancer is found through research. Meanwhile, the invention discloses a definite anti-tumor molecular target spot of the UDCA, and provides a theoretical basis for new application of clinical old medicines of the UDCA.

The present invention relates to a pharmaceutical composition for preventing or treating cholestatic liver disease, comprising beta-lapachone and ursodeoxycholic acid as active ingredients. Specifically, by orally administering beta-lapachone and ursodeoxycholic acid in combination, the composition is expected to contribute to the treatment of patients with primary sclerosing cholangitis or inflammatory bowel disease accompanied by primary sclerosing cholangitis, which are difficult to treat, by reducing the concentration of TNF-alpha in the blood of the patients and by also significantly reducing the severity of primary sclerosing cholangitis.

This invention discloses a cinnamylursodeoxycholic acid compound, its preparation method, pharmaceutical composition, and applications. The compound has the structure of Formula 1 or Formula 2, and also includes its stereoisomers, geometric isomers, tautomers, deuterated compounds, pharmaceutically acceptable salts, or mixtures thereof. This class of compounds exhibits highly efficient inhibitory activity against inflammatory cells and significantly inhibits NO production, while also possessing low cytotoxicity, making it suitable for preparation as an anti-inflammatory drug. Furthermore, the preparation method for this class of compounds is simple and facilitates structural expansion.

The present invention relates to a composition comprising (1) a cyclic peptide or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable solvate thereof, and (2) ursodeoxycholic acid or a pharmaceutically acceptable salt thereof.

The invention discloses an intelligent response type bear gall powder-based bioactive ceramic hydrogel wound repair system, belongs to the technical field of biomedical materials, and solves the problems of function splitting, uncontrollable release and unreasonable interface bonding of an existing wound dressing. According to the system, intelligent response type hydrogel, bioactive ceramic and bear gall powder active ingredients are innovatively combined through dynamic coordination bonds; wherein a coordinate bond formed by an active group of the bear gall powder and metal ions released by the ceramic is used as an intelligent switch and can respond to pH / ROS change of a wound surface, and antibacterial ions and anti-inflammatory components are precisely controlled in a controlled release manner; meanwhile, the stable and dynamic compounding of the ceramic and the gel is realized through the bond; according to the invention, organic unification of intelligent response, multi-element biological activity and stable structure is realized, and antibacterial, anti-inflammatory, repair-promoting and wound healing quality-improving effects can be realized synergistically.

The utility model relates to the technical field of ursodesoxycholic acid production equipment, and discloses a temperature regulating device for continuous production of ursodesoxycholic acid, which comprises a shell, the inner wall of the shell is in threaded connection with a threaded cylinder I, the lower surface of the threaded cylinder I is fixedly connected with a fixed seat, the upper surface of the fixed seat is fixedly connected with a battery, and the battery is fixedly connected with a temperature regulating valve. A connecting plate is fixedly connected to the upper surface of the battery, a second threaded cylinder is fixedly connected to the upper surface of the connecting plate, a quick release assembly is arranged on the inner wall of the connecting plate and comprises an electric heating tube, and the outer wall of the electric heating tube is slidably connected to the inner wall of the connecting plate. According to the electric heating device, the button is pressed down, so that the button overcomes the thrust of the spring and slides down along the inner wall of the limiting groove, meanwhile, the telescopic rod shrinks, and after the button is completely separated from the limiting state, the electric heating tube is rotated to a designated position in the connecting groove, and the electric heating tube slides down. Therefore, the effect that the electric heating tube is pulled out of the connecting plate along the connecting groove is achieved.

The application relates to the medical technical field, in particular to application of sulfasalazine in preparation of a medicine for treating primary biliary cholangitis (PBC) which is poorly responsive to ursodeoxycholic acid (UDCA), aiming at the clinical problem that about 40% of PBC patients are poorly responsive to the first-line drug UDCA, have high disease progression risk and limited second-line treatment options, and providing a new treatment use of the mature drug sulfasalazine. Through prospective clinical research, it is confirmed that, on the basis of UDCA standard treatment, combined use of sulfasalazine (1.5g / day, a treatment course of 48 weeks) can significantly improve liver biochemical indexes of UDCA non-responders, including alkaline phosphatase and gamma-glutamyltransferase, and 62.5% of the patients reach composite biochemical response. The application provides a new, effective, safe and highly accessible second-line treatment strategy for PBC patients who are poorly responsive to UDCA, and has a good clinical application prospect.

The present disclosure relates to genetically engineered microorganisms for the production of progesterone and / or ursodesoxycholic acid by fermentation.

A method for preparing a key intermediate 7K of ursodeoxycholic acid (UDCA). The key intermediate 7K of UDCA is prepared from BA by means of eight steps of reaction below: first subjecting the raw material BA to sulfonylation and then to alkylation with a malonic diester so as to construct a 21-position side chain, in which steps, sulfonylation and alkylation proceed readily, the conditions are mild, and there are few by-products and impurities; and then subjecting same to ketal protection, oxidation, hydrolysis, hydrogenation, hydrolysis and decarboxylation.

The invention discloses an application of ursodesoxycholic acid UDCA in inhibition of Skp2 protein and resistance to non-small cell lung cancer, and particularly discloses an application of ursodesoxycholic acid UDCA in preparation of an Skp2 protein inhibitor, the ursodesoxycholic acid UDCA inhibits Skp2 to enable a cell cycle to be stagnated in a G0 / G1 phase, so that degradation of p21Cip1 and p27Kip1 is reduced. Meanwhile, the invention discloses application of ursodesoxycholic acid UDCA in preparation of a non-small cell lung cancer cell proliferation activity inhibitor. The ursodesoxycholic acid UDCA is reported to have relatively strong Skp2 protein inhibition capability and non-small cell lung cancer inhibition capability for the first time, is simple in structure, is one of main components of bile acid in bear gall powder, is also a chemical drug capable of being artificially synthesized, can be stably separated and extracted, and has a good application prospect. The compound is a natural antitumor compound which is efficient and easy to obtain.

The application provides a preparation method and intermediates of ursodeoxycholic acid. The preparation method uses commercially available compound A as a raw material, and ursodeoxycholic acid is prepared through multiple step reactions. The raw material of compound A is widely available and cheap. The preparation method of the application has mild reaction conditions, does not require special reagents, has simple post-treatment, is simple to operate, and is suitable for industrial production.

This invention provides a method for preparing an intermediate of ursodeoxycholic acid. The method includes asymmetric reduction hydrogenation of a compound of formula VI to obtain a compound of formula VII. The purity and content of the isomers of the obtained product are significantly improved, providing a new method for chiral control in the preparation of ursodeoxycholic acid. This invention also provides a method for preparing ursodeoxycholic acid from dichlorol via asymmetric reduction and other reactions. This method has advantages such as readily available raw materials from plant-derived fermentation, low cost, short reaction time, high product purity, and high yield, making it suitable for industrial production.

Methods and consumer products for detecting a metabolite, the method comprising: testing a urine sample from a subject for a metabolite selected from the group consisting of ascorbate, dehydroascorbate, CEHC-sulfate, CEHC-taurine, CEHC-glucronide, pantoate, 5-amino valerate, galactonate, phenylacetylalanine, methylcatecholsulfate, phenylacetylglutamine, carboxysuccinate, carboxyethylvaline, arabinose, threonate, methylcrotonylglycine, glucuronate, carboxyethylisoleucine, glycoursodeoxycholate, leucylalanine, lithocholatesulfate, alio-threonine, cholic, glucuronide and combinations thereof; and producing a metabolic profile for the metabolite.

The ursodesoxycholic acid particles capable of being dissolved out rapidly and stably are provided, gelatin is used for solubilizing, and unexpectedly, the gelatin has a solubilizing effect when the ph value is 6.8 or 7.5, but does not have a solubilizing effect when the ph value is 1.2 or 4.5. The particles can be quickly released in the intestinal tract and are not released in the stomach. The invention further provides the ursodesoxycholic acid directly-taken granules with taste masking and good taste, the ursodesoxycholic acid directly-taken granules are good in taste under the condition that rapid and stable dissolution is guaranteed, and the ursodesoxycholic acid directly-taken granules can be taken after being mixed with water and can also be directly swallowed without water.